Skip to main content

A phase 1b study of RVU120, a novel CDK8 inhibitor, in patients with AML or high-risk MDS


Ryvu Therapeutics


TAP Partner

Project Term: August 7, 2017 - December 31, 2023

In August 2017, LLS TAP partnered with Ryvu Therapeutics (formerly known as Selvita) to support "A Phase Ib Study of SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome." SEL120 (RVU120) is a highly selective first-in-class CDK8/CDK19 inhibitor that was discovered with the Ryvu Therapeutics discovery engine platform. CDK8 plays a unique and critical role in gene regulation and is implicated in the development of numerous hematological malignancies and solid tumors. In preclinical studies, SEL120 has shown strong proof of concept for the treatment of AML, a disease with a poor prognosis. Ryvu is conducting an open-label, dose-escalation study at multiple sites in the United States to evaluate the safety, tolerability and preliminary activity of SEL120 and to establish a recommended dose for further clinical development.

Lay Abstract

For additional information, please visit

Therapy Acceleration Program
To All Projects